Navigation Links
Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
Date:5/26/2010

MOUNTAIN VIEW, Calif. May 26, 2010 Complete Genomics Inc., a third-generation human genome sequencing company, today announced that Genentech Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), used the company's sequencing, bioinformatics and analytics services to sequence and compare a patient's primary lung tumor and adjacent normal tissue. Tumor-normal pairs like this allow researchers to compare the patient's genome before and after it was altered by the cancer; the patient's normal genome serves as the ideal control. This is the first time that such a comparison has been made across the whole genome for a lung cancer patient. Genentech's findings will be published online in Nature later today in a paper titled "The mutation spectrum revealed by paired genome sequences from a lung cancer patient."

Complete Genomics sequenced the patient's cancer and normal genome to a depth of 60x and 46x, respectively, providing high-resolution results and allowing somatic variations to be called with high confidence. This depth of sequencing enabled the Genentech researchers to identify a large number of somatic mutations and structural variations in the non-small cell lung cancer genome.

Using Complete Genomics' sequencing service, the Genentech team, led by Dr. Zemin Zhang, senior scientist, was able to detect significantly more somatic variations than have been discovered in other cancer studies (leukemia and breast cancer) conducted on a genome-wide basis. Genentech identified more than 50,000 high-confidence somatic single nucleotide variations (SNVs), which yielded an estimated genome-wide somatic mutation rate of 17.7 per Mb.

The Genentech researchers validated 392 somatic SNVs in coding regions, including one in the KRAS proto-oncogene. They also validated 43 large-scale structural variations in the tumor.

In addition, the researchers observed a distinct pattern of selection against mutations within expressed genes compared to non-expressed genes and in promoter regions up to 5 kb upstream of all protein-coding genes. This is the first time that such selection pressures within a tumor environment have been clearly identified.


'/>"/>

Contact: Lisa Osborne
lisao@waggeneredstrom.com
206-992-5245
Complete Genomics
Source:Eurekalert

Related medicine news :

1. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
2. UCSF enters drug discovery agreement with Genentech
3. UCSF Enters Drug Discovery Agreement with Genentech
4. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
5. Now with Augmented Reality, Life Compass, by Fortune Compass, is the most complete Feng Shui App in Apple's iTunes store!
6. Impact Systems Successfully Completes EMC Documentum Migration for Global Pharmaceutical Client
7. LeveragePoint Releases Complete Online Value Management Solution
8. Vinomis Laboratories Completes Additional Funding Round
9. The Kramer Group Completes Strategic Name Change to Kramer Healthcare Technologies
10. CyberlinkASP Completes SAS 70 Type II Audit at Dallas Datacenter
11. Complete revascularization improves outcomes for CAD patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
Breaking Medicine Technology: